Edit
Molecular Instruments, Inc.
https://www.molecularinstruments.com/Last activity: 08.09.2026
Active
The HCR™ imaging platform opens a new era for RNA fluorescence in situ hybridization (RNA-FISH) and immunofluorescence (IF), enabling simultaneous multiplex, quantitative, high-resolution RNA and protein imaging in the anatomical context of thick autofluorescent samples, with 1-step, isothermal, enzyme-free HCRsignal amplification for all RNA and protein targets simultaneously.
Location: United States
Investors 1
| Date | Name | Website |
| - | Freeflow V... | freeflow.i... |
Mentions in press and media 4
| Date | Title | Description |
| 08.09.2026 | Molecular Instruments Announces HCR™ Gold IF for Multiplex Protein Imaging on Biocare Medical’s ONCORE Pro X | - |
| 25.06.2026 | Molecular Instruments Advances Automated Multiplex Tissue Research with HCR™ Gold IF on the BOND RX Research Staining Instrument | Molecular Instruments® (MI), founded by the inventor of HCR™ technology, today announced the release of HCR™ Gold IF on the BOND RX research staining instrument from Leica Biosystems, a Danaher company and global leader in end-to-end anatom... |
| 23.02.2026 | Molecular Instruments Announces Fully Ambient-Temperature HCR™ Pro RNA-ISH on the BOND-III, Setting a New Standard for Clinical Automation | Molecular Instruments® (MI), inventor of the HCR™ technology, today announced the availability of fully ambient-temperature HCR™ Pro RNA-ISH on the BOND-III, introducing a new class of clinical-grade RNA-ISH engineered for consistency, tiss... |
| 19.11.2025 | Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry | Molecular Instruments® (MI), the inventor of the HCR™ imaging platform, and Standard BioTools Inc. (NASDAQ: LAB) today announced a strategic collaboration to develop next-generation Imaging Mass Cytometry™ (IMC™) workflows powered by HCR im... |